Page 108 - Read Online

Cadamuro et al. Hepatoma Res 2022;8:11 https://dx.doi.org/10.20517/2394-5079.2021.140 Page 13 of 16

mice. Stem Cells 2015;33:3569-80. DOI PubMed
25. Fabris L, Cadamuro M, Cagnin S, Strazzabosco M, Gores GJ. Liver matrix in benign and malignant biliary tract disease. Semin Liver
Dis 2020;40:282-97. DOI PubMed
26. Mertens JC, Fingas CD, Christensen JD, et al. Therapeutic effects of deleting cancer-associated fibroblasts in cholangiocarcinoma.
Cancer Res 2013;73:897-907. DOI PubMed PMC
27. Cadamuro M, Nardo G, Indraccolo S, et al. Platelet-derived growth factor-D and Rho GTPases regulate recruitment of cancer-
associated fibroblasts in cholangiocarcinoma. Hepatology 2013;58:1042-53. DOI PubMed PMC
28. Vaquero J, Aoudjehane L, Fouassier L. Cancer-associated fibroblasts in cholangiocarcinoma. Curr Opin Gastroenterol 2020;36:63-9.
DOI PubMed
29. Brivio S, Cadamuro M, Strazzabosco M, Fabris L. Tumor reactive stroma in cholangiocarcinoma: the fuel behind cancer
aggressiveness. World J Hepatol 2017;9:455-68. DOI PubMed PMC
30. Kuperwasser C, Chavarria T, Wu M, et al. Reconstruction of functionally normal and malignant human breast tissues in mice. Proc
Natl Acad Sci U S A 2004;101:4966-71. DOI PubMed PMC
31. Gascard P, Tlsty TD. Carcinoma-associated fibroblasts: orchestrating the composition of malignancy. Genes Dev 2016;30:1002-19.
DOI PubMed PMC
32. Stacker SA, Williams SP, Karnezis T, Shayan R, Fox SB, Achen MG. Lymphangiogenesis and lymphatic vessel remodelling in
cancer. Nat Rev Cancer 2014;14:159-72. DOI PubMed
33. Cadamuro M, Brivio S, Mertens J, et al. Platelet-derived growth factor-D enables liver myofibroblasts to promote tumor
lymphangiogenesis in cholangiocarcinoma. J Hepatol 2019;70:700-9. DOI PubMed
34. Kim H, Kataru RP, Koh GY. Inflammation-associated lymphangiogenesis: a double-edged sword? J Clin Invest 2014;124:936-42.
DOI PubMed PMC
35. Thelen A, Scholz A, Benckert C, et al. Microvessel density correlates with lymph node metastases and prognosis in hilar
cholangiocarcinoma. J Gastroenterol 2008;43:959-66. DOI PubMed
36. Thelen A, Scholz A, Benckert C, et al. Tumor-associated lymphangiogenesis correlates with lymph node metastases and prognosis in
hilar cholangiocarcinoma. Ann Surg Oncol 2008;15:791-9. DOI PubMed
37. Mantovani A, Marchesi F, Malesci A, Laghi L, Allavena P. Tumour-associated macrophages as treatment targets in oncology. Nat
Rev Clin Oncol 2017;14:399-416. DOI PubMed PMC
38. Duluc D, Delneste Y, Tan F, et al. Tumor-associated leukemia inhibitory factor and IL-6 skew monocyte differentiation into tumor-
associated macrophage-like cells. Blood 2007;110:4319-30. DOI PubMed
39. Rőszer T. Understanding the mysterious M2 macrophage through activation markers and effector mechanisms. Mediators Inflamm
2015;2015:816460. DOI PubMed PMC
40. Hasita H, Komohara Y, Okabe H, et al. Significance of alternatively activated macrophages in patients with intrahepatic
cholangiocarcinoma. Cancer Sci 2010;101:1913-9. DOI PubMed
41. Paillet J, Kroemer G, Pol JG. Immune contexture of cholangiocarcinoma. Curr Opin Gastroenterol 2020;36:70-6. DOI PubMed
42. Dalen FJ, van Stevendaal MHME, Fennemann FL, Verdoes M, Ilina O. Molecular repolarisation of tumour-associated macrophages.
Molecules 2018;24:9. DOI PubMed PMC
43. Pathria P, Louis TL, Varner JA. Targeting tumor-associated macrophages in cancer. Trends Immunol 2019;40:310-27. DOI PubMed
44. Loilome W, Bungkanjana P, Techasen A, et al. Activated macrophages promote Wnt/β-catenin signaling in cholangiocarcinoma cells.
Tumour Biol 2014;35:5357-67. DOI PubMed PMC
45. Boulter L, Guest RV, Kendall TJ, et al. WNT signaling drives cholangiocarcinoma growth and can be pharmacologically inhibited. J
Clin Invest 2015;125:1269-85. DOI PubMed PMC
46. Henze AT, Mazzone M. The impact of hypoxia on tumor-associated macrophages. J Clin Invest 2016;126:3672-9. DOI PubMed
PMC
47. Liu S, Jiang J, Huang L, et al. iNOS is associated with tumorigenicity as an independent prognosticator in human intrahepatic
cholangiocarcinoma. Cancer Manag Res 2019;11:8005-22. DOI PubMed PMC
48. Thanee M, Loilome W, Techasen A, et al. Quantitative changes in tumor-associated M2 macrophages characterize
cholangiocarcinoma and their association with metastasis. Asian Pac J Cancer Prev 2015;16:3043-50. DOI PubMed
49. Zhou M, Wang C, Lu S, et al. Tumor-associated macrophages in cholangiocarcinoma: complex interplay and potential therapeutic
target. EBioMedicine 2021;67:103375. DOI PubMed PMC
50. Chiossone L, Dumas PY, Vienne M, Vivier E. Natural killer cells and other innate lymphoid cells in cancer. Nat Rev Immunol
2018;18:671-88. DOI PubMed
51. Carnevale G, Carpino G, Cardinale V, et al. Activation of Fas/FasL pathway and the role of c-FLIP in primary culture of human
cholangiocarcinoma cells. Sci Rep 2017;7:14419. DOI PubMed PMC
52. Wendel M, Galani IE, Suri-Payer E, Cerwenka A. Natural killer cell accumulation in tumors is dependent on IFN-gamma and
CXCR3 ligands. Cancer Res 2008;68:8437-45. DOI PubMed
53. Fukuda Y, Asaoka T, Eguchi H, et al. Endogenous CXCL9 affects prognosis by regulating tumor-infiltrating natural killer cells in
intrahepatic cholangiocarcinoma. Cancer Sci 2020;111:323-33. DOI PubMed PMC
54. Jung IH, Kim DH, Yoo DK, et al. In vivo study of natural killer (NK) cell cytotoxicity against cholangiocarcinoma in a nude mouse
model. In Vivo 2018;32:771-81. DOI PubMed PMC
55. Morisaki T, Umebayashi M, Kiyota A, et al. Combining cetuximab with killer lymphocytes synergistically inhibits human
cholangiocarcinoma cells in vitro. Anticancer Res 2012;32:2249-56. PubMed